GLAXO WELLCOME OFFERS QUIT SMOKING PILL
By Adnews Staff
Glaxo Wellcome Inc. of Mississauga, Ont. has developed a new way to help people stop smoking. The pharmaceutical giant has launched Zyban, a pill that attempts to work on the brain's addiction to nicotine. To take Zyban, smokers set a quit date and begin taking Zyban, while continuing to smoke one to two weeks prior to their quit date. They usually take the drug for seven to 12 weeks with the help of a personalized support program. Zyban costs about $1.60 a day. Glaxo Wellcome will promote the drug using print ads in medical journals. The ads will be created by Ogilvy & Mather of Toronto. PR will be handled by Hill & Knowlton of Toronto. Glaxo Wellcome develops, manufactures and markets medicines for the treatment of migraines, asthma, HIV/AIDS, cancer, gastrointestinal and cardiovascular disorders.